Form 4: Lyell COO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Operating Officer, Stephen J. Hill, sold shares to cover tax withholding obligations from vested restricted stock units.

Summary

• Stephen J. Hill, Chief Operating Officer of Lyell Immunopharma, Inc. (LYEL), reported two sales of common stock.
• On August 11, 2025, 91 shares were sold at a weighted average price of $10.526 per share, with prices ranging from $10.045 to $11.00.
• On August 12, 2025, an additional 94 shares were sold at a weighted average price of $10.338 per share, with prices ranging from $10.120 to $10.415.
• Both sales were automatically executed to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following these transactions, Stephen J. Hill beneficially owns 8,849 shares of common stock.
• The reported share amounts reflect a 1-for-20 reverse stock split effected by the Issuer on May 30, 2025.
• The beneficial ownership also includes 390 shares acquired on May 18, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary sales by an executive to cover tax obligations related to vested equity. This type of transaction is neutral in sentiment as it does not reflect a change in the executive's confidence in the company's prospects or operational performance.

Positives

• The acquisition of 390 shares under the Issuer's 2021 Employee Stock Purchase Plan indicates ongoing employee participation and investment in the company.
• The sales were non-discretionary, specifically to cover tax withholding obligations, which is a routine and expected event for executives receiving equity compensation, rather than a signal of lack of confidence in the company.

Negatives

• The total beneficial ownership of common stock by the Chief Operating Officer decreased by 185 shares due to the sales.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details routine insider transactions for tax withholding purposes, which are common across all industries for executives who receive equity compensation. It does not provide specific insights into Lyell Immunopharma's competitive position or broader industry trends in the biotechnology or immunopharma sector.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or management's long-term view.
• Employees: The acquisition of shares through the Employee Stock Purchase Plan indicates continued employee participation in the company's equity, which can be a positive for employee alignment.

Key Dates

Recommendation

The filing details routine, non-discretionary sales by a company officer to cover tax obligations related to vested restricted stock units. Such transactions are common and do not typically reflect a change in the officer's confidence in the company's future or its operational performance. Therefore, this specific filing does not provide new information that would warrant a change in investment stance.

Keywords

Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Stephen J. Hill, Reverse Stock Split, Employee Stock Purchase Plan